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Abstract
Objective—Recent research indicates that n-3 fatty acids can inhibit cognitive decline, perhaps 
differentially by hypertensive status.
Design—We tested these hypotheses in a prospective cohort study (ARIC). Dietary assessment 
using an FFQ and plasma exposure by gas chromatography were completed in 1987-89 (visit 1), 
while cognitive assessment with three screening tools DWRT, DSST/WAIS-R and WFT, was 
completed in 1990-92 (visit 2) and 1996-98 (visit 4). Regression calibration and simulation 
extrapolation (SIMEX) were used to control for measurement error in dietary exposures.
Setting—Four US communities: Forsyth County (NC), Jackson (MS), suburbs of Minneapolis 
(MN), and Washington County (MD).
Subjects—Men and women aged 50-65 years at visit 1 with complete dietary data (n=7,814); 
White men and women in same age group in the MN field center with complete plasma fatty acid 
data (n=2,251).
Results—Findings indicated that increase by 1 SD of dietary long chain n-3 fatty acids (% of 
energy intake) and balancing long-chain n-3/n-6 decreased the risk of six-year cognitive decline in 
verbal fluency subjects with odds ratios of 0.79 (95%CI: 0.66-0.95) and 0.81 (95% CI: 0.68-0.96), 
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respectively among hypertensives. An interaction with hypertensive status was found for dietary 
long-chain n-3 fatty acids (in grams/day) and WFT decline (LR test p=0.06). This exposure in 
plasma cholesteryl esters was also protective against WFT decline, particularly among 
hypertensives (OR: 0.51, p<0.05).
Conclusion—One implication from our study is that diets rich in fatty acids of marine origin 
should be considered for middle aged hypertensive subjects. To this end, randomized clinical trials 
are needed.
Keywords
Fatty acids; cognitive decline; hypertension; regression calibration; simulation extrapolation; 
dietary assessment
The proportion of the US population ages 65 and over was 12.3 percent in 2000 based on 
recent United Nations estimates and is projected to increase rapidly in the coming decades to 
reach 20 percent by 2050 1. As populations age, all cognitive disorders, including dementia, 
become more common. Recent research indicates that n-3 fatty acids may be important in 
preventing cognitive decline. So far, epidemiological evidence, although inconclusive, 
suggests a protective effect of n-3 fatty acid intake in the diet 2-4. Essential fatty acids are 
linked to several biochemical and biophysical functions, including structural integrity and 
fluidity of membranes, enzyme activities, lipid-protein interactions and serving as precursors 
for eicosanoids such as prostaglandins, leukotrienes and thromboxanes 5. The fatty acid 
composition of neuronal cell membrane phospholipids reflects their intake in the diet 6 and 
fish oils, which contain high levels of C20 and C22 polyunsaturated fatty acids (PUFAs), 
exert the most profound influence on brain PUFA concentration. According to experimental 
animal studies, there is a plausible pathway by which hypertension and low dietary n-3 fatty 
acid intake may interact in increasing the risk of cognitive decline. In fact, hypertensive rats 
tended to have lower brain MUFAs and PUFAs than normotensive rats 7, possibly due to 
pressure-induced endothelial dysfunction at the blood-brain barrier or exhausted astrocytic 
metabolism. Oxidative stress which accompanies high blood pressure leads to increased 
peroxidation of unsaturated fatty acids and a reduction in their concentration in the brain 
represents an alternative explanation.
Despite animal experimental evidence for a possible biological interaction between dietary 
intake of n-3 fatty acids and hypertensive status 7-10 in affecting cognitive decline, no 
epidemiological study to date has attempted to test this hypothesis. The present 
observational prospective study assessed the effect of low n-3 fatty acid status on six-year 
cognitive decline in men and women aged 50 years and older. A secondary objective was to 
explore whether hypertensive subjects would benefit to a larger extent than normotensive 
subjects from this increased intake.
Data and Methods
Study Sample
Atherosclerosis Risk in Communities (ARIC) is an ongoing prospective cohort study aimed 
at investigating the etiology of atherosclerosis and its clinical sequelae and the longitudinal 
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impact of variation in cardiovascular risk factors, medical care, and disease by race, sex, 
place, and time. In each of four US communities--Forsyth County (NC), Jackson (MS), 
suburbs of Minneapolis (MN), and Washington County (MD)-- 4,000 adults aged 45-64 
years were examined four times, three years apart (visits 1 through 4). Three out of the four 
cohorts represented the ethnic mix of their communities, while at Jackson, MS, only African 
American residents were recruited 11. Out of the total sample examined at baseline 
(N=15,792) we restricted these analyses to 11,557 individuals aged 50 years or older at 
baseline. Out of the total sample examined at baseline (N=15,792), we restricted these 
analyses to 11,557 individuals aged 50 years or older at baseline since research clearly 
shows that risk of cognitive decline in general, and of dementia in particular, is negligible 
prior to the age of 60 years (which is the age at which the youngest individuals in this cohort 
were re-examined in visit 4) 12. Eligibility for these analyses further required survival 
through visit 4 (n=8,346), complete data on cognitive functioning at visits 2 (1990-92) and 4 
(1996-98) yielding a sample size of 8,012 and also complete dietary intake at visit 1 
(1987-89), which yielded n=7,814 men and women. Of these, plasma fatty acid data at visit 
1 was available on a sub-set of the Minneapolis cohort, MN (n=2,251).
Outcome assessment
Three measures of cognitive functioning were made only for visits 2 and 4 among the total 
ARIC cohort, and these measures relied on the following instruments: Delayed Word Recall 
Test (DWRT) Delayed Word Recall Test (DWRT) 14; the Digit Symbol Substitution portion 
of the Revised Weschler Adult Intelligence Scale (DSST/WAIS-R) 15, and Word Fluency 
Test (WFT) of the Multilingual Aphasia Examination, also known as the controlled oral 
word association 16.
The Delayed Word Recall Test (DWRT): This screening tool assesses verbal learning and 
recent memory. It requires the respondent to recall 10 common words after a 5-minute 
interval during which another test is administered. Test scores may range between 0 and 10 
words recalled and the time limit for recall is set at 60 seconds. The 6-months test-retest 
reliability of DWRT was previously shown to be high among 26 normal elderly individuals 
(Pearson correlation coefficient, r=0.75) 14.
The Digit Symbol Substitution (DSST/WAIS-R): This test is a paper-and-pencil test 
requiring timed translation of numbers 1 through 9 to symbols using a key. The test 
measures psychomotor performance and is relatively unaffected by intellectual ability, 
memory, or learning for most adults16. It appears to be a sensitive and reliable marker of 
brain damage17. The test score can range between 0 and 93 and it reflects the correctly 
translated number of digit-symbol pairs within a time limit of 90 seconds. Short-term test-
retest reliability over 2-5 weeks has been found to be high in individuals aged 45-54 years 
(r=0.82) 15.
The Word Fluency Test (WFT): This test requires subjects to record as many words as 
possible using the initial letters F, A and S and to list these words, the subject is given only 
60 seconds per letter. The total score corresponds to the total number of words generated 
during these three trials. The test is particularly sensitive to linguistic impairment 1618 and 
early mental decline in older persons 19. It is also a sensitive marker of damage in the left 
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lateral frontal lobe 1618. The immediate test-retest correlation coefficient based on an 
alternate test form has been found to be high (r=0.82) 20.
Preliminary analysis suggested that while visits 2 and 4 scores of DSST and WFT had a 
correlation coefficient close to 0.5, correlations between DSST and DWRT were 0.4 and 
between DWRT and WFT around 0.4. However, cognitive changes (V4-V2) in each of these 
scales had much weaker correlations with each others ranging between 0.06 and 0.09.
Cutoff points were determined for decline in each of three cognitive status tests using the 
Reliable Change Index (RCI) method in order to correct for measurement error and practice 
effects 21. RCI is defined as ((X2-X1)-(M2-M1))/S.E.D., where X1 is the individual's score at 
baseline, X2 the individual's score at follow-up, M1 and M2 are the group mean pretest and 
follow-up scores respectively, and S.E.D. the observed standard error of the difference 
scores. Scoring below an RCI of -1.645 was regarded as a “statistically reliable” 
deterioration in the test scores.
A composite measure of the three RCIs to assess global cognitive decline (GCD) was 
created using principal components analysis (PCA), a data reduction technique 22. Similarly, 
the cutoff point of the composite score for statistically reliable global cognitive decline was 
chosen to be -1.645.
Exposure Assessment
Usual dietary intake was estimated from an interviewer-administered 61-item semi-
quantitative food frequency questionnaire (FFQ) previously developed and validated by W. 
Willet and colleagues against multiple food records among a sub-sample of the Nurse's 
Health Study cohort 23. Dietary intake of essential fatty acids and their elongated and 
desaturated products were expressed as percent of total energy intake and grouped under 
four main categories, as suggested by Lands and colleagues 2425: (3P) n-3 C18 
polyunsaturated fatty acids: 18:3+18:4n-3 (6P) n-6 C18 polyunsaturated fatty acids: 
18:2+18:3n-6 (3H) n-3 C20 and C22 highly unsaturated fatty acids (HUFAs): 
20:5+22:5+22:6n-3 and (6H) n-6 HUFAs: 20:3+20:4+22:4+22:5n-6. Sums of fatty acid 
intake as percent of energy included (3)= (3P)+(3H) and (6)=(6P)+(6H). Ratios of interest 
included (3P)/(6P), (3H)/(6H) and (3P+3H)/(6P+6H) also denoted as 3/6. In multivariate 
models, all these variables were standardized by subtracting each observation from the 
variable mean and dividing the difference by the standard deviation. Hence, the main 
exposures of interest were 3P, 3H, 3 (as percent of energy intake), 3P/6P, 3H/6H, 3/6, and 
total 3H (in grams per day). Adjustment was made for the other fatty acid variables, and 
total energy intake was considered as a potential confounder to emulate a multivariate 
nutrient density model26.
Twelve-hour fasting blood was collected according to the ARIC study wide protocol. The 
Minneapolis field center conducted fatty acid analysis of plasma phospholipid and 
cholesteryl ester fractions on visit 1 blood specimens. The procedure is described in detail 
elsewhere 27. The identity of 28 fatty acid peaks were revealed by gas chromatography by 
comparing each peak's retention time to the retention times of fatty acids in synthetic 
standards of known compositions. The relative amount of each fatty acid (as a percent of all 
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fatty acids) was calculated by integrating the area under the peak, dividing the result by the 
total area for all fatty acids, and multiplying by 100. Data from the chromatogram were 
transferred electronically to a computer for analysis. Plasma exposures are expressed as % of 
total fatty acids in each fraction and were grouped similarly to dietary exposure. Test-retest 
reliability coefficients (individuals sampled 3 times, 2 weeks apart) for various plasma fatty 
acids ranged from 0.50 to 0.93 for cholesteryl esters to 0.89 for phospholipids28. However, 
only 3H and the ratio of 3H/6H were considered in these analyses.
Replicate dietary measures
Dietary intake was assessed among the surviving ARIC sample at visit 3 (1992-94), using 
the same semi-quantitative food frequency questionnaire that was administered at baseline. 
At visit 2, a sub-sample of ARIC (around 10% of the original sample) was asked to repeat 
the FFQ. As stated earlier, of our eligible subset with baseline data on exposure and 
complete outcome data (n=7,814), 657 had data on visit 2 exposure, 7,482 had complete 
data at visit 3, while 634 had both.
Covariates
Most covariates considered as potential confounders were measured at visit 1, although 
some were defined according to criteria that spanned all four visits. Covariates can be 
subdivided into socio-demographic, genetic, health behaviors and nutritional. Age, gender, 
ethnicity and education were all reported by the respondent. Apo E genotype was 
categorized as 0 to indicate the absence of an ε4 allele vs.1 to denote carrier status for at 
least one ε4 allele. Among the behavioral factors (all measured at visit 1), smoking was 
represented on a three-level categorical scale, namely: never smoked, smoked previously and 
current smoker. Food frequency questionnaire derived values of alcohol (grams/day) and 
caffeine (mg/day) were considered as well. Physical activity was assessed using a 
questionnaire developed by Baecke and colleagues, including 16 items about usual 
exertion 29. A validated index of physical activity was derived at visit 1, summing sports, 
work and leisure indices which ranged from a score of 1 (low) to 5 (high) 30. Body mass 
index at visit 1 was computed by dividing weight in kilograms by the height-squared (in 
square meters). Baseline dietary intake of antioxidants and other micronutrients (mainly 
Vitamins B6, B12 and folate) was considered as well 23. The association of these covariates 
with our outcome has been previously documented by similar cohort studies based on ARIC 
data 31-34.
Our main effect modifier, hypertension, was operationalized using measured systolic and 
diastolic blood pressure at each visit as well as use of anti-hypertensive medication over the 
past two weeks. Seated blood pressure levels were calculated as the average of the second 
and third of three consecutive measurements with a random-zero sphygmomanometer and 
hypertension was defined as ≥ 140 mm Hg. for SBP and ≥ 90 mm Hg. for DBP or the use of 
anti-hypertensive medication during the past two weeks prior to examination on any of visits 
1 through 4.
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We carried out univariate analyses of predictor and outcome variables as well as covariates. 
For bivariate analyses of exposure and outcome, we computed means of predictor variables 
across outcome groups (0 = no decline; 1= decline) and assessed statistical significance of 
differences using independent samples t-test at an alpha level of 0.05. We computed odds 
ratios of decline with increase in each exposure by 1 SD through a multivariate logistic 
regression analysis. Control for confounding was accomplished using backward elimination 
and an overall change in estimate criterion of 5%. Covariates which changed the estimated 
effect of the exposure by more than 5% were retained in the final model 35.
Hypertension was considered as a potential effect modifier. Likelihood ratio tests were used 
to assess statistical significance of interaction between exposure and hypertensive status at a 
type I error level of 0.20, after obtaining the final parsimonious model 3637. The multivariate 
models can be summarized by equations (1) and (2):
(1)
(2)
In the above equations, Q1 is the main exposure of interest as derived from the food 
frequency questionnaire, Q2i are the other fatty acids that might act as confounders, Zj is a 
vector of potential confounders that are assumed to be perfectly measured (i.e. no error 
variance associated with them), and H is the potential effect modifier “hypertensive status” 
also assumed to be perfectly measured. The same process was used with the plasma 
exposures in cholesteryl esters and phospholipids. To correct for measurement error in 
dietary exposure, a sensitivity analysis was conducted for models (1) and (2) whereby 
regression calibration and simulation extrapolation were applied to the final parsimonious 
models for each outcome/exposure pair 3839. In a multivariate setting, both RCAL and 
SIMEX rely on the method of moments and attempt to estimate the error variance in the 
error-prone exposure and adjust the exposure-outcome effect using different procedures. In 
both cases, replicate measures of FFQ measurements at visits 2 and 3 were used for the 
correction. The two methods are described in more detail in the online Appendix. Statistical 
analyses were conducted using STATA ver. 9.0 40.
Results
Characteristics of study subjects
Table 1 shows the characteristics of study subjects according to availability of dietary and 
plasma fatty acid data as well as cognitive assessment data at both points in time. Subjects in 
the plasma fatty acid group consisted of whites residing in the suburbs of Minneapolis. They 
were in general more educated than the dietary group, which was a mix from all ARIC 
centers. They had a lower proportion of women (50.7% vs. 54.63%), a lower prevalence of 
the ApoEε4 allele (28.8% vs. 30.0%), a higher proportion “ever smoked” status (59.5% vs. 
55.4%), and greater consumption of alcohol and caffeine. Some differences were noted for 
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other behavioral and nutritional factors as well. Hypertensive status was particularly high in 
the dietary group (56%) compared to 49% among the plasma group. Raw mean scores of 
baseline cognitive function were greater among those in the plasma compared to the dietary 
group and average declines between visits 2 and 4 were found to be steeper in the former. 
Table 2 summarizes the distribution of dietary and plasma fatty acid exposures considered. 
Standard deviations (SD) for Q1, M and N are of particular importance in interpreting 
multivariate logistic regression analysis. Q2 and Q3 represent replicate measurements on Q1 
at visits 2 and 3 which were used to correct for measurement error in the exposure.
Multivariate analysis findings: dietary exposures
Multivariate logistic regression of the relationship between dietary exposure and cognitive 
decline is presented in Table 3. Results indicate that risk of clinically significant decline in 
DWRT over the period of 6 years was reduced modestly with every standard deviation 
increase in long-chain n-3 fatty acid intake (3H) as % of total energy intake. This was 
observed in the total population and among the hypertensive subgroup. For DSST/WAIS-R, 
although the ratio 3H/6H was protective against decline, this effect did not reach statistical 
significance. However, the likelihood ratio test indicated a significant level of interaction 
between this exposure and hypertensive status, shown by the variation in effect across strata 
of the effect modifier (1.09 among normotensives vs. 0.88 among hypertensives). Risk of 
decline in WFT was reduced by long chain and all types of n-3 fatty acid intake (3H and 3) 
as % of total energy intake, and by the ratio of 3H/6H and 3H in grams/day. This 
relationship was stronger among hypertensive subjects and a significant interaction was 
noted for 3H in grams/day (LR test p=0.06). No statistically significant results were 
observed for global cognitive decline or other dietary exposures. After adjusting for 
measurement error in the dietary covariate using regression calibration, loss of precision in 
measures of effect was observed. In most cases, bias seemed to be towards the null when 
comparing naïve and calibrated estimates. In few instances, significance of odds ratios was 
preserved, such as in the case of 3H, 3H(grams/day), 3 and 3H/6H with WFT decline as the 
outcome among the hypertensive stratum (data not shown). In these four exposures 
respectively, the calibrated odds ratios for WFT decline in the hypertensive stratum with 
their 95% CI were 0.68 (0.49, 0.95), 0.69 (0.47,1.00), 0.65 (0.43, 1.00) and 0.70 (0.52, 
0.95). Using SIMEX for selected associations, similar results were obtained. Figure 1 shows 
two examples of stratified models 3.2b and 3.2g of Table 3 (3H and ratio of 3H/6H's effect 
on decline in WFT). The figures show the extent to which naïve estimates are biased towards 
the null when compared to the corrected regression coefficients using the SIMEX method. 
This method is described in detail in the online appendix.
Multivariate analysis findings: plasma exposures
Multivariate logistic analyses of the plasma fatty acid data (Table 4) indicated generally 
lower odds of cognitive decline among subjects with a higher concentration of long chain 
n-3 fatty acid in their plasma cholesteryl esters and phospholipids, and an elevated ratio of 
long chain n-3/n-6 fatty acids. An interaction was noted between WFT for absolute 3H in 
cholesteryl esters (OR: 0.74 among normotensives vs. 0.51 among hypertensives) without 
reaching statistical significance at the level of 0.10 (p=0.25). The same pattern was observed 
for the ratio of 3H/6H in cholesteryl esters and both exposures in the phospholipid fraction.
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This population-based prospective study conducted among middle-aged men and women at 
baseline showed that increased dietary intake of long chain n-3 fatty acids and balancing 
long-chain n-3/n-6 decreased the risk of cognitive decline in verbal fluency, particularly 
among hypertensive subjects. This finding also held for the corresponding plasma analytes 
in the cholesteryl ester and phospholipid fractions. This finding may be due to the higher 
sensitivity of WFT to early mental decline (i.e. among those aged 55 years or more at 
baseline) when compared to DWRT and DSST/WAIS-R 19. Limitations of the study include 
the lack of psychometric diagnosis for mild cognitive impairment, which might have been a 
more definite and clinically relevant outcome41. However, the neuropsychological tests used 
represent some of the domains reported to be most sensitive in discriminating between 
normal aging and mild cognitive impairment 42. Another limitation relates to the nature of 
dietary exposures in general which are often prone to measurement error both in terms of 
validity and short-term reliability. We corrected for validity by using an alloyed gold 
standard and two instrumental biomarkers but failed to correct for short-term reliability of 
the food frequency questionnaire due to the lack of adequate short-term replicates in ARIC. 
Nevertheless, a previous study by Ma and colleagues 28 provides estimate for short-term 
reliability of each of the fatty acids that were considered. Moreover, residual confounding 
due to inadequate control or measurement of potential confounders cannot be totally ruled 
out. It is important to note also that exposure timing (one year prior to visit 1) did not 
coincide with the baseline measurement of outcome (visit 2) which constitutes another 
major limitation.
One of the main strengths of this study is its prospective design which, as stated earlier, thus 
far is unique in the literature testing this particular hypothesis 43. An evidence-based report 
suggested a need to look for the effect of n-3 fatty acids on cognitive decline by 
cardiovascular disease status and to define exposure in terms of absolute value of medium 
chain and long chain fatty acids, as well as the ratio between n-3 and n-6 fatty acids in diet 
and plasma 44. All these suggestions were implemented in the present study. Moreover, this 
is the first study to assess effect modification by hypertensive status and to test at the 
population level a biological interaction documented in animal experimental work. 
Measurement error, which almost always accompanies dietary assessment, was corrected for 
in this study using regression calibration for all associations and SIMEX for a selected 
number of these associations.
Previous epidemiological studies have shown that the fatty acids composition of plasma 
differs significantly between subjects with normal cognitive functioning and patients with 
some form of cognitive impairment 45-47. While the majority showed a beneficial effect of 
plasma and erythrocyte n-3 fatty acids on cognition, a case-control study – the Canadian 
Study of Health and Ageing – reported that the mean relative plasma concentration of n-3 
fatty acids as well as total polyunsaturated fatty acids was higher among subjects aged 65 
years or more with cognitive impairment or dementia after controlling for demographic, 
behavioral and genetic factors 48. Epidemiological studies based on dietary assessments of 
n-3 fatty acids also had suggestive but somewhat controversial results. While most leaned 
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towards a protective effect of increasing intake of these fatty acids in the diet 2349-51, others 
found no effect or the opposite effect on cognitive functioning and decline 452.
One possibly important implication from our study's results is that diets rich in fatty acids of 
marine origin should be considered for middle aged subjects. We explored whether such an 
association was differential according to hypertensive status. Although no statistically 
significant interactions were found, the results suggest that hypertensive subjects (e.g. odds 
ratios for 3H and WFT were <1 with p<0.05) may benefit from supplementation of their 
diets to a larger extent than the normotensive group. These results merit replication given the 
large public health potential that would be associated with results that unequivocally indicate 
inverse association between fatty acid intake and reduced cognitive decline in the general 
population. The literature indicates that these fatty acids were frequently found associated 
with reduced risk of cardiovascular disease, including stroke 53 and coronary heart 
disease 5455, although thus far all the evidence is of an observational nature. They have also 
been associated with improved insulin sensitivity56, reduced risk of dyslipidemia 57 and a 
hypocoagulable profile 58 among other health benefits. Because many of these conditions 
are also related to cognitive impairment, future research should focus on disentangling the 
direct and indirect effects of fatty acids (using plasma biomarkers) on cognition and uncover 
the main mechanism involved in their ability to prevent clinically significant decline in aging 
populations. Finally, these findings suggest the utility of randomized clinical trials that 
would augment intake of marine fatty acids in the treatment group and give a non-enriched 
diet to the placebo group while allowing for stratification by baseline hypertensive status.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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ARIC Atherosclerosis Risk in Communities
DSST/WAIS-R Digit Symbol Substitution Test of the Wechsler Adult Intelligence Scale 
– Revised
DWRT Delayed Word Recall Test
FFQ Food Frequency Questionnaire
GBCF Global Baseline Cognitive Functioning
GCD Global Cognitive Decline
HUFA Highly Unsaturated Fatty Acids
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MCI Mild Cognitive Impairment
MUFA mono-unsaturated fatty acids
PCA Principal components analysis
PUFA Polyunsaturated fatty acids
RCAL Regression Calibration
RCI Reliable Change Index
SIMEX Simulation extrapolation
WFT Word Fluency Test
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Figure 1. SIMEX plot of corrected coefficients for stratified models 3b and 3e of Table 3; ARIC 
(1987-98)*
*pct3h: dietary intake of long chain n-3 fatty acids expressed as percentage of energy intake 
(3H); r3hr6h: ratio of long chain n-3 to long chain n-6 fatty acids (3H/6H). Lambda is 
equivalent to θ = {0.5, 1, 1.5, 2} and is a scale factor used to add error to the covariate and 
estimate βm= f(θ,βm59) starting from the naïve estimate in which θ = 0. Hence, the naïve 
estimate of the regression coefficient β is the one estimated by generalized linear models 
without measurement error correction. See online Appendix for more details.
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Table 1
Characteristics of study subjects with complete cognitive and dietary data between visits 1 
and 4 (Dietary group; N=7,814) and those with complete cognitive and plasma data 
(Plasma group; N=2,251); ARIC 1987-98
Dietary group (All ARIC centers) Plasma group (MN whites)
Characteristics Mean (%) (SD) Mean (%) (SD)
Female 54.63 50.69*
Age (years)† 56.56 (4.31) 56.30* (4.24)
White† 81.48 100.00*
Education†
 Incomplete high school 20.24 6.67*
 High School 34.06 36.18
 > High School 45.70 57.16
Apo E ε4 allele† 30.00 28.84
Smoking status†
 Never smoker 44.54 40.40*
 Former smoker 35.55 41.82
 Current smoker 19.91 17.78
Alcohol (g/day)† 5.88 (12.67) 8.08* (13.47)
Caffeine (mg/day)† 291.04 (290.82) 348.08* (325.93)
Physical activity scale† 7.06 (1.39) 7.33* (1.33)
Body mass index (kg/m2)† 27.48 (4.96) 27.17* (4.41)
Total energy intake (Kcal/day)† 1579 (571) 1581 (559)
Vitamin A (in 1000 IUs/day)† 9.13 (6.97) 8.65* (6.83)
Vitamin B6 (mg/day)† 1.75 (0.67) 1.74* (0.66)
Vitamin B12 (mcg/day)† 7.61 (4.23) 7.06* (3.50)
Vitamin C (mg/day)† 122.39 (80.92) 112.67* (69.95)
Vitamin E (mg/day)† 4.97 (3.11) 4.66* (3.01)
Folate (mcg/day)† 232.59 (101.18) 218.48* (94.97)
Hypertensive‡ 56.01 49.27*
Baseline cognitive scores (V2)§
 DWRT 6.61 (1.46) 6.78* (1.43)
 DSST/WAIS-R 45.02 (13.01) 51.65* (10.15)
 WFT 33.77 (12.06) 37.59* (11.52)
Cognitive change (V4-V2)§
 DWRT -0.17 (1.56) -0.21 (1.50)
 DSST/WAIS-R -2.80 (6.79) -4.45* (6.36)
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Dietary group (All ARIC centers) Plasma group (MN whites)
Characteristics Mean (%) (SD) Mean (%) (SD)
 WFT -0.77 (7.86) -1.84* (7.78)
*
P<0.05 for null hypothesis that means or proportions are equal between plasma and non-plasma groups.
†
Covariate measured at visit 1.
‡
Covariate measured at visits 1 through 4: period prevalence over 9 years.
§
Covariate with other time frame.
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